Market capitalization | $3.01m |
Enterprise Value | $9.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 19.60 |
P/S ratio (TTM) P/S ratio | 6.02 |
P/B ratio (TTM) P/B ratio | 1.87 |
Revenue growth (TTM) Revenue growth | -97.90% |
Revenue (TTM) Revenue | $500.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Exicure Inc:
1 Analyst has issued a forecast Exicure Inc:
Jun '24 |
+/-
%
|
||
Revenue | 0.50 0.50 |
98%
98%
|
|
Gross Profit | -0.44 -0.44 |
102%
102%
|
|
EBITDA | -5.03 -5.03 |
201%
201%
|
EBIT (Operating Income) EBIT | -5.97 -5.97 |
286%
286%
|
Net Profit | -8.17 -8.17 |
366%
366%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Head office | United States |
CEO | Paul Kang |
Employees | 6 |
Founded | 2011 |
Website | www.exicuretx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.